GREFFEX, INC.
AURORA, CO · CIK 0001439539 · Biotech · Private
Gene Transfer Vector Plug and Play Platform for gene therapy and vaccine development
greffex.com →- Grants
- $337K
- 2 awards
- Sector median: 1
- Raised
- $155K
- 1 Form D · Aug 2017
- 110 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 21
- 0 granted · 21 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201720182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $155,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of an Usher Gene Therapy | $227,497 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of an Usher Gene Therapy | $109,982 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2640 | Avant Sciences, Inc. | — | $175K |
| 2641 | Renova Therapeutics, Inc. | — | $167K |
| 2642 | BIONANOTECH LLC | — | — |
| 2643 | GREFFEX, INC. | — | $155K |
| 2644 | RITROVA THERAPEUTICS INC. | — | $150K |
| 2645 | SYMMETRIC COMPUTING, INC. | — | — |
| 2646 | Ajaya Bio, Inc. | — | $150K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Jehan Al-MeerDirector
- Sir Walter BodmerDirector
- William ConnollyDirector · Executive Officer
- John PriceDirector · Executive Officer
- Uwe StaerzDirector · Executive Officer
- Phillip ZobristDirector
Patents
- Gene Therapy For Retinal Diseasesapplication
- Design Of Optimized Universal Influenza Vaccines, Their Designs And Usesapplication
- Antibody Constructs To Target T Cell Responses To Sars-cov Protein Expressing Cells, Their Design And Usesapplication
- Multivalent Beta-coronavirus Vaccines, Their Designs And Usesapplication
- Enhancement Of The Production Of Adenovirus-based Gene Transfer Vectorsapplication
- Engineering Coronavirus Spike Proteins As Vaccine Antigens, Their Design And Usesapplication
- Engineering Broadly Reactive Coronavirus Vaccines And Related Designs And Usesapplication
- Maintaining Dna Fragments In Eukaryotic Cells, Approaches And Usesapplication
- Replication-deficient Avian Adenoviral Vectors, Their Design And Usesapplication
- Culture Systems For The Efficient Production Of Gene Transfer Vectorsapplication
- Adenovirus-mediated gene therapy for retinal diseaseapplication
- Culture Systems For The Efficient Production Of Gene Transfer Vectorsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.